85 results on '"Borchi, B."'
Search Results
2. WS13.03 Microbiology of upper and lower airways of cystic fibrosis (CF) patients in stable conditions and in lung transplant patients
- Author
-
Fevola, C., primary, Dolce, D., additional, Campana, S., additional, Ravenni, N., additional, Bianchimani, C., additional, Santini, G., additional, Francalanci, M., additional, Cavicchi, M.C., additional, Galici, V., additional, Neri, A.S., additional, Terlizzi, V., additional, Innocenti, D., additional, Masi, E., additional, Ferrari, B., additional, Castellani, C., additional, Masolini, M., additional, Camera, E., additional, Orioli, T., additional, Bresci, S., additional, Borchi, B., additional, Cavallo, A., additional, Mencarini, J., additional, Maggiore, G., additional, and Taccetti, G., additional
- Published
- 2023
- Full Text
- View/download PDF
3. 490 Evaluation of the BioFire FilmArray Pneumonia Panel Plus for diagnosis of lower respiratory tract infections in people with cystic fibrosis who have undergone lung transplantation
- Author
-
Fevola, C., primary, Campana, S., additional, Dolce, D., additional, Ravenni, N., additional, Bianchimani, C., additional, Francalanci, M., additional, Cavicchi, M., additional, Galici, V., additional, Neri, A., additional, Terlizzi, V., additional, Innocenti, D., additional, Ferrari, B., additional, Camera, E., additional, Orioli, T., additional, Bresci, S., additional, Borchi, B., additional, Cavallo, A., additional, Mencarini, J., additional, and Taccetti, G., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Valacyclovir for prevention and treatment of fetal CMV infection: inclusion in the Law 648/96 list and launch of the Italian multicentre observational prospective study 'MEGAL-ITALI'
- Author
-
Zammarchi, L., Lazzarotto, T., Di Tommaso, M., Tomasoni, L., Pasquini, L., Galli, L., Simonazzi, G., Castelli, F., Borchi, B., Campolmi, I., SARA ORNAGHI, Bartoloni, A., Andreoni, M., Pagano, I., Petraglia, S., Ramenghi, L., Clerici, P., Tavio, M., Trotta, M., Zammarchi L, Lazzarotto T, Di Tommaso M, Tomasoni L, Pasquini L, Galli L, Simonazzi G, Castelli F, Borchi B, Campolmi I, Ornaghi S, Bartoloni A, Andreoni M, Pagano I, Petraglia S, Ramenghi L, Clerici P, Tavio M, Trotta M., Zammarchi, L, Lazzarotto, T, Di Tommaso, M, Tomasoni, L, Pasquini, L, Galli, L, Simonazzi, G, Castelli, F, Borchi, B, Campolmi, I, Ornaghi, S, Bartoloni, A, Andreoni, M, Pagano, I, Petraglia, S, Ramenghi, L, Clerici, P, Tavio, M, and Trotta, M
- Subjects
Valacyclovir, Citomegalovirus, pregnancy ,Italy ,Valacyclovir ,Cytomegalovirus Infections ,Infant, Newborn ,Humans ,Infant ,Antiviral Agents ,Newborn ,valacyclovir, congenital, cytomegalovirus - Abstract
not available
- Published
- 2021
5. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients with COVID-19 Pneumonia: A Randomized Clinical Trial
- Author
-
Menichetti, F., Popoli, P., Puopolo, M., Alegiani, S. S., Tiseo, G., Bartoloni, A., De Socio, G., Luchi, S., Blanc, P., Puoti, M., Toschi, E., Massari, M., Palmisano, L., Marano, G., Chiamenti, M., Martinelli, L., Franchi, S., Pallotto, C., Suardi, L. R., Pasqua, B. L., Merli, M., Fabiani, P., Bertolucci, L., Borchi, B., Modica, S., Moneta, S., Marchetti, G., d'Arminio Monforte, A., Stoppini, L., Ferracchiato, N., Piconi, S., Fabbri, C., Beccastrini, E., Saccardi, R., Giacometti, A., Esperti, S., Pierotti, P., Bernini, L., Bianco, C., Benedetti, S., Lanzi, A., Bonfanti, P., Sani, S., Saracino, A., Castagna, A., Trabace, L., Lanza, M., Focosi, D., Mazzoni, A., Pistello, M., Falcone, M., Locatelli, F., Ippolito, G., Magrini, N., Bernardini, R., Brusaferro, S., De Angelis, V., Perotti, C., Remuzzi, G., De Silvestro, G., Costantini, M., Bocchino, M., De Donno, G., Francisci, D., Menichetti, F., Popoli, P., Puopolo, M., Spila Alegiani, S., Tiseo, G., Bartoloni, A., De Socio, G. V., Luchi, S., Blanc, P., Puoti, M., Toschi, E., Massari, M., Palmisano, L., Marano, G., Chiamenti, M., Martinelli, L., Franchi, S., Pallotto, C., Suardi, L. R., Luciani Pasqua, B., Merli, M., Fabiani, P., Bertolucci, L., Borchi, B., Modica, S., Moneta, S., Marchetti, G., D'Arminio Monforte, A., Stoppini, L., Ferracchiato, N., Piconi, S., Fabbri, C., Beccastrini, E., Saccardi, R., Giacometti, A., Esperti, S., Pierotti, P., Bernini, L., Bianco, C., Benedetti, S., Lanzi, A., Bonfanti, P., Sani, S., Saracino, A., Castagna, A., Trabace, L., Lanza, M., Focosi, D., Mazzoni, A., Pistello, M., Falcone, M., Menichetti, F, Popoli, P, Puopolo, M, Spila Alegiani, S, Tiseo, G, Bartoloni, A, De Socio, G, Luchi, S, Blanc, P, Puoti, M, Toschi, E, Massari, M, Palmisano, L, Marano, G, Chiamenti, M, Martinelli, L, Franchi, S, Pallotto, C, Suardi, L, Luciani Pasqua, B, Merli, M, Fabiani, P, Bertolucci, L, Borchi, B, Modica, S, Moneta, S, Marchetti, G, d'Arminio Monforte, A, Stoppini, L, Ferracchiato, N, Piconi, S, Fabbri, C, Beccastrini, E, Saccardi, R, Giacometti, A, Esperti, S, Pierotti, P, Bernini, L, Bianco, C, Benedetti, S, Lanzi, A, Bonfanti, P, Sani, S, Saracino, A, Castagna, A, Trabace, L, Lanza, M, Focosi, D, Mazzoni, A, Pistello, M, and Falcone, M
- Subjects
Male ,medicine.medical_specialty ,Randomization ,Settore MED/17 - Malattie Infettive ,Population ,Aged ,COVID-19 ,Disease Progression ,Female ,Humans ,Italy ,Middle Aged ,Prospective Studies ,SARS-CoV-2 ,Severity of Illness Index ,Standard of Care ,Hospital Mortality ,Hospitalization ,Immunization, Passive ,Plasma ,Respiratory Insufficiency ,Passive ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,Clinical endpoint ,medicine ,education ,Adverse effect ,education.field_of_study ,business.industry ,General Medicine ,Odds ratio ,medicine.disease ,Pneumonia ,Respiratory failure ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Immunization ,business - Abstract
Importance: Convalescent plasma (CP) has been generally unsuccessful in preventing worsening of respiratory failure or death in hospitalized patients with COVID-19 pneumonia. Objective: To evaluate the efficacy of CP plus standard therapy (ST) vs ST alone in preventing worsening respiratory failure or death in patients with COVID-19 pneumonia. Design, setting, and participants: This prospective, open-label, randomized clinical trial enrolled (1:1 ratio) hospitalized patients with COVID-19 pneumonia to receive CP plus ST or ST alone between July 15 and December 8, 2020, at 27 clinical sites in Italy. Hospitalized adults with COVID-19 pneumonia and a partial pressure of oxygen-to-fraction of inspired oxygen (Pao2/Fio2) ratio between 350 and 200 mm Hg were eligible. Interventions: Patients in the experimental group received intravenous high-titer CP (≥1:160, by microneutralization test) plus ST. The volume of infused CP was 200 mL given from 1 to a maximum of 3 infusions. Patients in the control group received ST, represented by remdesivir, glucocorticoids, and low-molecular weight heparin, according to the Agenzia Italiana del Farmaco recommendations. Main outcomes and measures: The primary outcome was a composite of worsening respiratory failure (Pao2/Fio2 ratio
- Published
- 2021
6. P142 Upper and lower airways microbiological status in cystic fibrosis patients in stable conditions and in lung transplant patients
- Author
-
Bianchimani, C., primary, Dolce, D., additional, Campana, S., additional, Ravenni, N., additional, Fevola, C., additional, Santini, G., additional, Francalanci, M., additional, Cavicchi, M.C., additional, Galici, V., additional, Neri, A.S., additional, Terlizzi, V., additional, Innocenti, D., additional, Masi, E., additional, Ferrari, B., additional, Castellani, C., additional, Masolini, M., additional, Camera, E., additional, Orioli, T., additional, Bresci, S., additional, Borchi, B., additional, Cavallo, A., additional, Mencarini, J., additional, Maggiore, G., additional, and Taccetti, G., additional
- Published
- 2022
- Full Text
- View/download PDF
7. Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen
- Author
-
Fabbiani, M, Zaccarelli, M, Latini, A, Sterrantino, G, DʼEttorre, G, Grima, P, Mondi, A, Rossetti, B, Borchi, B, Giuliani, M, Antinori, A, De Luca, A, and Di Giambenedetto, S
- Published
- 2016
- Full Text
- View/download PDF
8. Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020
- Author
-
Lagi, F., Piccica, M., Graziani, L., Vellere, I., Botta, A., Tilli, M., Ottino, L., Borchi, B., Pozzi, M., Bartalesi, F., Mencarini, J., Spinicci, M., Zammarchi, L., Pieralli, F., Zagli, G., Nozzoli, C., Romagnoli, S., Bartoloni, A., Campolmi, I., Di Lauria, N., Millotti, G., Basile, G., Meli, M., Rogasi, P. G., Bartolozzi, D., Corsi, P., Mazzetti, M., Farese, A., Bresci, S., Cavallo, A., Trotta, M., Corti, G., Morettini, A., Poggesi, L., de Gaudio, A. R., Peris, A., Fontanari, P., Parronchi, P., Almerigogna, F., Annunziato, F., Liotta, F., Cosmi, L., Vultaggio, A., Matucci, A., Angileri, M., Ipponi, A., Cecchi, M., Benemei, S., Vannucchi, A. M., Matucci Cerinic, Marco, and Turco, L.
- Subjects
0301 basic medicine ,Male ,Author's Correction ,Epidemiology ,COVID-19 ,Cohort ,Florence ,ICU ,Italy ,SARS-CoV-2 ,pandemic ,Age Distribution ,Aged ,Betacoronavirus ,Cannula ,Cohort Studies ,Comorbidity ,Contact Tracing ,Coronavirus Infections ,Critical Care ,Disease Outbreaks ,Female ,Humans ,Intensive Care Units ,Middle Aged ,Patient Transfer ,Pneumonia, Viral ,Respiratory Care Units ,Sex Distribution ,Treatment Outcome ,Coronavirus ,Pandemics ,Disease ,medicine.disease_cause ,law.invention ,0302 clinical medicine ,law ,Pandemic ,Medicine ,030212 general & internal medicine ,Intensive care unit ,Rapid Communication ,medicine.medical_specialty ,030106 microbiology ,03 medical and health sciences ,Virology ,business.industry ,Public Health, Environmental and Occupational Health ,Outbreak ,Tropical disease ,medicine.disease ,Emergency medicine ,business ,Contact tracing - Abstract
We analysed the first 84 coronavirus disease (COVID-19) patients hospitalised in an infectious and tropical disease unit in Florence, Italy, over 30 days after the start of the COVID-19 outbreak in Italy. A 12% reduction in the rate of intensive care unit transfer was observed after the implementation of intensity care measures in the regular ward such as increasing the nurse/patient ratio, presence of critical care physicians and using high flow nasal cannulae oxygenation.
- Published
- 2020
9. P262 Respiratory microbiological patterns and comparison in patients with CFTR-related disorders, cystic fibrosis and non-cystic fibrosis bronchiectasis
- Author
-
Basile, G., Carducci, C., Borchi, B., Cavallo, A., Mencarini, J., Mannini, C., Terlizzi, V., Taccetti, G., Vaggelli, G., Campana, S., Lavorini, F., Bartoloni, A., and Bresci, S.
- Published
- 2023
- Full Text
- View/download PDF
10. P231 Monitoring of respiratory tract infections of cystic fibrosis transplanted patients by means of a multiplex PCR assay
- Author
-
Fevola, C., Campana, S., Dolce, D., Ravenni, N., Bianchimani, C., Francalanci, M., Cavicchi, M.C., Galici, V., Neri, A.S., Terlizzi, V., Camera, E., Orioli, T., Bresci, S., Borchi, B., Cavallo, A., Mencarini, J., and Taccetti, G.
- Published
- 2023
- Full Text
- View/download PDF
11. P060 Measurement of the plasma concentration of elexacaftor/tezacaftor/ivacaftor (ETI) by LC/MS-MS in a patient with cystic fibrosis during pregnancy
- Author
-
Mattei, M.L., Francalanci, E., Streva, N., Bresci, S., Cavallo, A., Mencarini, J., Malcontenti, C., Cini, N., Luceri, F., Fanelli, A., Pistelli, A., and Borchi, B.
- Published
- 2023
- Full Text
- View/download PDF
12. Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series
- Author
-
Floridia M, Masuelli G, Meloni A, Cetin I, Tamburrini E, Cavaliere AF, Dalzero S, Sansone M, Alberico S, Guerra B, Spinillo A, Chiadò Fiorio Tin M, Ravizza M, Mori F, Ortolani P, Dalle Nogare ER, Di Lorenzo F, Sterrantino G, Meli M, Polemi S, Nocentini J, Baldini M, Montorzi G, Mazzetti M, Rogasi P, Borchi B, Vichi F, Del Pin B, Pinter E, Anzalone E, Marocco R, Mastroianni C, Mercurio VS, Carocci A, Grilli E, Maccabruni A, Zaramella M, Mariani B, Natalini Raponi G, Guaraldi G, Nardini G, Stentarelli C, Beghetto B, Degli Antoni AM, Molinari A, Crisalli MP, Donisi A, Piepoli M, Cerri V, Zuccotti G, Giacomet V, Coletto S, Di Nello F, Madia C, Placido G, Vivarelli A, Castelli P, Savalli F, Portelli V, Sabbatini F, Francisci D, Bernini L, Grossi P, Rizzi L, Maso G, Airoud M, Soppelsa G, Dedoni M, Cuboni C, Ortu F, Piano P, Citernesi A, Bordoni Vicini I, Luzi K, Roccio M, Vimercati A, Miccolis A, De Gennaro A, Cervi F, Simonazzi G, Margarito E, Capretti MG, Marsico C, Faldella G, Martinelli P, Agangi A, Capone A, Maruotti GM, Tibaldi C, Trentini L, Todros T, Frisina V, Brambilla T, Savasi V, Personeni C, Giaquinto C, Fiscon M, Rubino E, Bucceri A, Matrone R, Scaravelli G, Genovese O, Cafforio C, Pinnetti C, Liuzzi G, Tozzi V, Massetti P, Casadei AM, Cellini M, Castelli Gattinara G, Marconi AM, Sacchi V, Ierardi M, Polizzi C, Mattei A, Pirillo MF, Amici R, Galluzzo CM, Donnini S, Baroncelli S, Villani P, Cusato M, Cerioli A, De Martino M, Mastroiacovo P, Parazzini F, Vella S., Floridia M, Masuelli G, Meloni A, Cetin I, Tamburrini E, Cavaliere AF, Dalzero S, Sansone M, Alberico S, Guerra B, Spinillo A, Chiadò Fiorio Tin M, Ravizza M, and Mori F, Ortolani P, Dalle Nogare ER, Di Lorenzo F, Sterrantino G, Meli M, Polemi S, Nocentini J, Baldini M, Montorzi G, Mazzetti M, Rogasi P, Borchi B, Vichi F, Del Pin B, Pinter E, Anzalone E, Marocco R, Mastroianni C, Mercurio VS, Carocci A, Grilli E, Maccabruni A, Zaramella M, Mariani B, Natalini Raponi G, Guaraldi G, Nardini G, Stentarelli C, Beghetto B, Degli Antoni AM, Molinari A, Crisalli MP, Donisi A, Piepoli M, Cerri V, Zuccotti G, Giacomet V, Coletto S, Di Nello F, Madia C, Placido G, Vivarelli A, Castelli P, Savalli F, Portelli V, Sabbatini F, Francisci D, Bernini L, Grossi P, Rizzi L, Maso G, Airoud M, Soppelsa G, Dedoni M, Cuboni C, Ortu F, Piano P, Citernesi A, Bordoni Vicini I, Luzi K, Roccio M, Vimercati A, Miccolis A, De Gennaro A, Cervi F, Simonazzi G, Margarito E, Capretti MG, Marsico C, Faldella G, Martinelli P, Agangi A, Capone A, Maruotti GM, Tibaldi C, Trentini L, Todros T, Frisina V, Brambilla T, Savasi V, Personeni C, Giaquinto C, Fiscon M, Rubino E, Bucceri A, Matrone R, Scaravelli G, Genovese O, Cafforio C, Pinnetti C, Liuzzi G, Tozzi V, Massetti P, Casadei AM, Cellini M, Castelli Gattinara G, Marconi AM, Sacchi V, Ierardi M, Polizzi C, Mattei A, Pirillo MF, Amici R, Galluzzo CM, Donnini S, Baroncelli S, Villani P, Cusato M, Cerioli A, De Martino M, Mastroiacovo P, Parazzini F, Vella S.
- Subjects
Infectious Disease Transmission ,Prenatal diagnosis ,HIV Infections ,0302 clinical medicine ,Birth defect ,Pregnancy ,Odds Ratio ,Vertical ,Medicine ,030212 general & internal medicine ,Pregnancy Complications, Infectious ,education.field_of_study ,Amniocentesi ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,Obstetrics ,Infectious ,Obstetrics and Gynecology ,Amniocentesis ,birth defects ,chorionic villus sampling ,HIV ,invasive testing ,mother-to child HIV transmission ,pregnancy ,prenatal diagnosis ,Birth defects ,Chorionic villus sampling ,Invasive testing ,Mother-to child HIV transmission ,Anti-Retroviral Agents ,Chorionic Villi Sampling ,Female ,Adult ,medicine.medical_specialty ,Prenatal diagnosi ,Population ,Settore MED/17 - MALATTIE INFETTIVE ,03 medical and health sciences ,Humans ,education ,Fetal Death ,Analysis of Variance ,Chi-Square Distribution ,business.industry ,Infectious Disease Transmission, Vertical ,Odds ratio ,medicine.disease ,Confidence interval ,Pregnancy Complications ,business ,Chi-squared distribution - Abstract
Objectives To assess in pregnant women with HIV the rates of amniocentesis and chorionic villus sampling (CVS), and the outcomes associated with such procedures. Design Observational study. Data from the Italian National Program on Surveillance on Antiretroviral Treatment in Pregnancy were used. Setting University and hospital clinics. Population Pregnant women with HIV. Methods Temporal trends were analysed by analysis of variance and by the Chi-square test for trend. Quantitative variables were compared by Student's t-test and categorical data by the Chi-square test, with odds ratios and 95% confidence intervals calculated. Main outcome measures Rate of invasive testing, intrauterine death, HIV transmission. Results Between 2001 and 2015, among 2065 pregnancies in women with HIV, 113 (5.5%) had invasive tests performed. The procedures were conducted under antiretroviral treatment in 99 cases (87.6%), with a significant increase over time in the proportion of tests performed under highly active antiretroviral therapy (HAART) (100% in 2011–2015). Three intrauterine deaths were observed (2.6%), and 14 pregnancies were terminated because of fetal anomalies. Among 96 live newborns, eight had no information available on HIV status. Among the remaining 88 cases with either amniocentesis (n = 75), CVS (n = 12), or both (n = 1), two HIV transmissions occurred (2.3%). No HIV transmission occurred among the women who were on HAART at the time of invasive testing, and none after 2005. Conclusions The findings reinforce the assumption that invasive prenatal testing does not increase the risk of HIV vertical transmission among pregnant women under suppressive antiretroviral treatment. Tweetable abstract No HIV transmission occurred among women who underwent amniocentesis or CVS under effective anti-HIV regimens.
- Published
- 2016
13. Syphilis in pregnancy in Florence: immigration and unfaithfulness: 2.1-013
- Author
-
Zammarchi, L., Trotta, M., Borchi, B., Bianchi, S., and Guerrini, E.
- Published
- 2011
14. Late-onset rhabdomyolysis in pneumococcal meningitis: a case report
- Author
-
Bartalesi, F., Borchi, B., Grilli, E., Corti, G., and Bartoloni, A.
- Published
- 2007
- Full Text
- View/download PDF
15. Antimicrobial resistance in an intensive care unit before adopting an antibiotic rotation programme for empiric therapy of ventilator-associated pneumonia: P1072
- Author
-
Corti, G., Mangani, V., Pecile, P., Borchi, B., Grilli, E., Nicoletti, P., Tulli, G., and Paradisi, F.
- Published
- 2005
16. Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV
- Author
-
Ravizza, M., Tamburrini, E., Mori, F., Ortolani, P., dalle Nogare, E.R., Di Lorenzo, F., Sterrantino, G., Meli, M., Polemi, S., Nocentini, J., Baldini, M., Montorzi, G., Mazzetti, M., Rogasi, P., Borchi, B., Vichi, F., Del Pin, B., Pinter, E., Anzalone, E., Marocco, R., Mastroianni, C., Mercurio, V.S., Carocci, A., Grilli, E., Maccabruni, A., Zaramella, M., Mariani, B., Natalini Raponi, G., Guaraldi, G., Nardini, G., Stentarelli, C., Beghetto, B., Degli Antoni, A.M., Molinari, A., Crisalli, M.P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Coletto, S., Di Nello, F., Madia, C., Placido, G., Vivarelli, A., Castelli, P., Savalli, F., Portelli, V., Sabbatini, F., Francisci, D., Bernini, L., Grossi, P., Rizzi, L., Alberico, S., Maso, G., Airoud, M., Soppelsa, G., Meloni, A., Dedoni, M., Cuboni, C., Ortu, F., Piano, P., Citernesi, A., Bordoni Vicini, I., Luzi, K., Spinillo, A., Roccio, M., Vimercati, A., Miccolis, A., De Gennaro, A., Guerra, B., Cervi, F., Simonazzi, G., Margarito, E., Capretti, M.G., Marsico, C., Faldella, G., Sansone, M., Martinelli, P., Agangi, A., Capone, A., Maruotti, G.M., Tibaldi, C., Trentini, L., Todros, T., Masuelli, G., Frisina, V., Cetin, I., Brambilla, T., Savasi, V., Personeni, C., Giaquinto, C., Fiscon, M., Rubino, E., Bucceri, A., Matrone, R., Scaravelli, G., Genovese, O., Cafforio, C., Pinnetti, C., Liuzzi, G., Tozzi, V., Massetti, P., Casadei, A.M., Cavaliere, A.F., Cellini, M., Castelli Gattinara, G., Marconi, A.M., Dalzero, S., Sacchi, V., Ierardi, M., Polizzi, C., Mattei, A., Pirillo, M.F., Amici, R., Galluzzo, C.M., Donnini, S., Baroncelli, S., Floridia, M., Villani, P., Cusato, M., Cerioli, A., De Martino, M., Mastroiacovo, P., Parazzini, F., Vella, S., and Degli Antoni, A.
- Published
- 2016
- Full Text
- View/download PDF
17. Good prenatal detection rate of major birth defects in HIV-infected pregnant women in Italy
- Author
-
Floridia, M, Mastroiacovo, P., Ravizza, M., Todros, T., Chiadò Fiorio Tin, M., Marconi, A. M., Cetin, I., Maruotti, G. M., Liuzzi, G., Pinnetti, C., Degli Antoni, A., Spinillo, A., Guerra, B., Tamburrini, E., Floridia, M., Mori, F., Ortolani, P., dalle Nogare, E. R., Di Lorenzo, F., Sterrantino, G., Meli, M., Polemi, S., Nocentini, J., Baldini, M., Montorzi, G., Mazzetti, M., Rogasi, P., Borchi, B., Vichi, F., Del Pin, B., Pinter, E., Anzalone, E., Marocco, R., Mastroianni, C., Mercurio, V. S., Carocci, A., Grilli, E., Maccabruni, A., Zaramella, M., Mariani, B., Natalini Raponi, G., Guaraldi, G., Nardini, G., Stentarelli, C., Beghetto, B., Degli Antoni, A. M., Molinari, A., Crisalli, M. P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Coletto, S., Di Nello, F., Madia, C., Placido, G., Vivarelli, A., Castelli, P., Savalli, F., Portelli, V., Sabbatini, F., Francisci, Daniela, Bernini, L., Grossi, P., Rizzi, L., Alberico, S., Maso, G., Airoud, M., Soppelsa, G., Meloni, A., Dedoni, M., Cuboni, C., Ortu, F., Piano, P., Citernesi, A., Bordoni Vicini, I., Luzi, K., Roccio, M., Vimercati, A., Miccolis, A., De Gennaro, A., Cervi, F., Puccetti, C., Margarito, E., Contoli, M., Capretti, M. G., Marsico, C., Faldella, G., Sansone, M., Martinelli, P., Agangi, A., Capone, A., Tibaldi, C., Trentini, L., Masuelli, G., Frisina, V., Brambilla, T., Savasi, V., Personeni, C., Giaquinto, C., Fiscon, M., Rinaldi, R., Rubino, E., Bucceri, A., Matrone, R., Scaravelli, G., Fundarò, C., Genovese, O., Cafforio, C., Tozzi, V., Massetti, P., Casadei, A. M., Cavaliere, A. F., Finelli, V., Cellini, M., Castelli Gattinara, G., Dalzero, S., Sacchi, V., Ierardi, M., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Villani, P., Cusato, M., Cerioli, A., De Martino, M., Parazzini, F., and Vella, S.
- Subjects
Adult ,Infectious ,Obstetrics and Gynecology ,HIV Infections ,Congenital Abnormalities ,Pregnancy Complications ,Italy ,Pregnancy ,Humans ,Female ,Pregnancy Complications, Infectious ,Genetics (clinical) - Published
- 2015
18. Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study
- Author
-
Floridia, M., Ravizza, M., Masuelli, G., Giacomet, V., Martinelli, P., Degli Antoni, A., Spinillo, A., Fiscon, M., Francisci, D., Liuzzi, G., Pinnetti, C., Marconi, A. M., Tamburrini, E., Mori, F., Ortolani, P., dalle Nogare, E. R., Di Lorenzo, F., Sterrantino, G., Meli, M., Polemi, S., Nocentini, J., Baldini, M., Montorzi, G., Mazzetti, M., Rogasi, P., Borchi, B., Vichi, F., Del Pin, B., Pinter, E., Anzalone, E., Marocco, R., Mastroianni, C., Mercurio, V. S., Carocci, A., Grilli, E., Maccabruni, A., Zaramella, M., Mariani, B., Natalini Raponi, G., Guaraldi, Giovanni, Nardini, Giulia, Stentarelli, Chiara, Beghetto, Barbara, Degli Antoni, A. M., Molinari, A., Crisalli, M. P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Fabiano, V., Placido, G., Vivarelli, A., Castelli, P., Savalli, F., Portelli, V., Sabbatini, F., Bernini, L., Grossi, P., Rizzi, L., Alberico, S., Maso, G., Airoud, M., Soppelsa, G., Meloni, A., Dedoni, M., Cuboni, C., Ortu, F., Piano, P., Citernesi, A., Bordoni Vicini, I., Luzi, K., Roccio, M., Vimercati, A., Miccolis, A., Bassi, E., Guerra, B., Cervi, F., Puccetti, C., Murano, P., Contoli, M., Capretti, M. G., Marsico, C., Faldella, G., Sansone, M., Agangi, A., Tibaldi, C., Trentini, L., Todros, T., Frisina, V., Cetin, I., Brambilla, T., Savasi, V., Personeni, C., Giaquinto, C., Rinaldi, R., Rubino, E., Bucceri, A., Matrone, R., Scaravelli, G., Fundaro, C., Genovese, O., Cafforio, C., Tozzi, V., Massetti, P., Casadei, A. M., Cavaliere, A. F., Finelli, V., Cellini, M., Castelli Gattinara, G., Dalzero, S., Sacchi, V., De Pirro, A., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Regazzi, M., Villani, P., Cusato, M., Cerioli, A., De Martino, M., Mastroiacovo, P., Moroni, M., Parazzini, F., Vella, S., Floridia, M, Ravizza, M, Masuelli, G, Giacomet, V, Martinelli, Pasquale, Degli Antoni, A, Spinillo, A, Fiscon, M, Francisci, D, Liuzzi, G, Pinnetti, C, Marconi, Am, Tamburrini, E, on behalf of The Italian Group on Surveillance on Antiretroviral Treatment in, Pregnancy, Floridia, M1, Italian Group on Surveillance on Antiretroviral Treatment in, P. r. e. g. n. a. n. c. y., Marco Floridia, Marina Ravizza, Giulia Masuelli, Vania Giacomet, Pasquale Martinelli, Anna Degli Antoni, Arsenio Spinillo, Marta Fiscon, Daniela Francisci, Giuseppina Liuzzi, Carmela Pinnetti, Anna Maria Marconi, Enrica Tamburrini, on behalf of The Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy [.., Capretti, M.G., Marsico, C., Faldella, G., and ].
- Subjects
Pyridines ,Pyridine ,HIV Infections ,Triglyceride ,Lopinavir ,Liver Function Tests ,Pregnancy ,HIV Infection ,Pharmacology (medical) ,Viral ,Pregnancy Complications, Infectious ,triglycerides ,pre-term delivery ,medicine.diagnostic_test ,Liver Function Test ,Obstetrics ,Medicine (all) ,Pregnancy Outcome ,Infectious ,virus diseases ,HIV ,pregnancy ,RNA ,Lipid ,Viral Load ,Lipids ,Infectious Diseases ,Tolerability ,Oligopeptide ,Population study ,RNA, Viral ,Female ,medicine.symptom ,bilirubin ,Viral load ,Oligopeptides ,Human ,medicine.drug ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,HIV RNA ,Anti-HIV Agents ,Atazanavir Sulfate ,Infectious Disease ,Bilirubin ,Cholesterol ,Pre-term delivery ,Triglycerides ,Pharmacology ,cholesterol ,Settore MED/17 - MALATTIE INFETTIVE ,medicine ,Humans ,business.industry ,Anti-HIV Agent ,medicine.disease ,Atazanavir ,CD4 Lymphocyte Count ,Pregnancy Complications ,Immunology ,Pregnancy Complications, Infectiou ,business ,Liver function tests ,Weight gain - Abstract
BACKGROUND: Atazanavir and lopinavir represent the main HIV protease inhibitors recommended in pregnancy, but comparative data in pregnant women are limited. METHODS: Women from a national observational study, exposed in pregnancy to either atazanavir or lopinavir, were compared for glucose and lipid profiles, liver function tests, CD4 count, HIV RNA and main pregnancy outcomes. Statistical methods included univariate and multivariable analyses. RESULTS: The study population included 428 pregnancies (lopinavir, 322; atazanavir, 106). The lopinavir group was characterized by higher rates of HIV diagnosis in pregnancy and treatment indication for maternal health, lower CD4 counts, higher HIV RNA levels, less frequent antiretroviral treatment at conception and shorter duration of drug exposure during pregnancy. No differences in pregnancy outcomes, glucose metabolism and weight gain were observed. The two groups also showed in a multivariable analysis similar odds for detectable HIV RNA in the third trimester (adjusted OR 0.85, 95% CI 0.35-2.10, P = 0.730). Total lipid levels were significantly higher in the lopinavir group (median values in the third trimester 239 versus 221 mg/dL for total cholesterol and 226 versus 181 mg/dL for triglycerides; P < 0.001 for both comparisons) and bilirubin levels were significantly higher in the atazanavir group (1.53 versus 0.46 mg/dL, P < 0.001). CONCLUSIONS: In this observational study atazanavir and lopinavir showed similar safety and activity in pregnancy, with no differences in the main pregnancy outcomes. Atazanavir use was associated with a better lipid profile and with higher bilirubin levels. Overall, the study findings confirm that these two HIV protease inhibitors represent equally valid alternative options.
- Published
- 2014
19. Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV
- Author
-
Floridia, M., primary, Pirillo, M.F., additional, Degli Antoni, A., additional, Molinari, A., additional, Tamburrini, E., additional, Pinnetti, C., additional, Guaraldi, G., additional, Nardini, G., additional, Masuelli, G., additional, Dalzero, S., additional, Cetin, I., additional, Sansone, M., additional, Amici, R., additional, Ravizza, M., additional, Mori, F., additional, Ortolani, P., additional, dalle Nogare, E.R., additional, Di Lorenzo, F., additional, Sterrantino, G., additional, Meli, M., additional, Polemi, S., additional, Nocentini, J., additional, Baldini, M., additional, Montorzi, G., additional, Mazzetti, M., additional, Rogasi, P., additional, Borchi, B., additional, Vichi, F., additional, Del Pin, B., additional, Pinter, E., additional, Anzalone, E., additional, Marocco, R., additional, Mastroianni, C., additional, Mercurio, V.S., additional, Carocci, A., additional, Grilli, E., additional, Maccabruni, A., additional, Zaramella, M., additional, Mariani, B., additional, Natalini Raponi, G., additional, Stentarelli, C., additional, Beghetto, B., additional, Degli Antoni, A.M., additional, Crisalli, M.P., additional, Donisi, A., additional, Piepoli, M., additional, Cerri, V., additional, Zuccotti, G., additional, Giacomet, V., additional, Coletto, S., additional, Di Nello, F., additional, Madia, C., additional, Placido, G., additional, Vivarelli, A., additional, Castelli, P., additional, Savalli, F., additional, Portelli, V., additional, Sabbatini, F., additional, Francisci, D., additional, Bernini, L., additional, Grossi, P., additional, Rizzi, L., additional, Alberico, S., additional, Maso, G., additional, Airoud, M., additional, Soppelsa, G., additional, Meloni, A., additional, Dedoni, M., additional, Cuboni, C., additional, Ortu, F., additional, Piano, P., additional, Citernesi, A., additional, Bordoni Vicini, I., additional, Luzi, K., additional, Spinillo, A., additional, Roccio, M., additional, Vimercati, A., additional, Miccolis, A., additional, De Gennaro, A., additional, Guerra, B., additional, Cervi, F., additional, Simonazzi, G., additional, Margarito, E., additional, Capretti, M.G., additional, Marsico, C., additional, Faldella, G., additional, Martinelli, P., additional, Agangi, A., additional, Capone, A., additional, Maruotti, G.M., additional, Tibaldi, C., additional, Trentini, L., additional, Todros, T., additional, Frisina, V., additional, Brambilla, T., additional, Savasi, V., additional, Personeni, C., additional, Giaquinto, C., additional, Fiscon, M., additional, Rubino, E., additional, Bucceri, A., additional, Matrone, R., additional, Scaravelli, G., additional, Genovese, O., additional, Cafforio, C., additional, Liuzzi, G., additional, Tozzi, V., additional, Massetti, P., additional, Casadei, A.M., additional, Cavaliere, A.F., additional, Cellini, M., additional, Castelli Gattinara, G., additional, Marconi, A.M., additional, Sacchi, V., additional, Ierardi, M., additional, Polizzi, C., additional, Mattei, A., additional, Galluzzo, C.M., additional, Donnini, S., additional, Baroncelli, S., additional, Floridia, M., additional, Villani, P., additional, Cusato, M., additional, Cerioli, A., additional, De Martino, M., additional, Mastroiacovo, P., additional, Parazzini, F., additional, and Vella, S., additional
- Published
- 2016
- Full Text
- View/download PDF
20. 104 Monitoring and treatment of non tuberculous mycobacteria (NTM): a difficult task
- Author
-
Galici, V., primary, Bresci, S., additional, Borchi, B., additional, Cavallo, A., additional, Taccetti, G., additional, Simonetti, M.T., additional, and Braggion, C., additional
- Published
- 2016
- Full Text
- View/download PDF
21. Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy
- Author
-
Floridia, M., Ravizza, M., Masuelli, G., Dalzero, S., Pinnetti, C., Cetin, I., Meloni, A., Spinillo, A., Rubino, E., Francisci, D., Tamburrini, E., Mori, F., Ortolani, P., Dalle Nogare, E. R., Di Lorenzo, F., Sterrantino, G., Meli, M., Polemi, S., Nocentini, J., Baldini, M., Montorzi, G., Mazzetti, M., Rogasi, P., Borchi, B., Vichi, F., Pinter, E., Anzalone, E., Marocco, R., Mastroianni, Claudio Maria, Mercurio, V. S., Carocci, A., Grilli, E., Maccabruni, A., Zaramella, M., Mariani, B., Natalini Raponi, G., Guaraldi, G., Luzi, K., Nardini, G., Stentarelli, C., Degli Antoni, A. M., Molinari, A., Crisalli, M. P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Fabiano, V., Placido, G., Vivarelli, A., Castelli, P., Savalli, F., Portelli, V., Sabbatini, F., Bernini, L., Alberico, S., Maso, G., Tropea, M., Dedoni, M., Cuboni, C., Ortu, F., Piano, P., Citernesi, A., Vicini, I., Roccio, M., Vimercati, A., Miccolis, A., Bassi, E., Guerra, B., Cervi, F., Puccetti, C., Murano, P., Contoli, M., Capretti, M. G., Marsico, C., Faldella, G., Sansone, M., Martinelli, P., Agangi, A., Tibaldi, C., Trentini, L., Todros, T., Garetto, S., Brambilla, T., Savasi, V., Crepaldi, A., Giaquinto, C., Fiscon, M., Rinaldi, R., Bucceri, A., Matrone, R., Scaravelli, G., Fundaro, C., Genovese, O., Cafforio, C., Liuzzi, G., Tozzi, V., Massetti, Anna Paola, Anceschi, M., Casadei, A. M., Cavaliere, A. F., Finelli, V., Cellini, M., Castelli Gattinara, G., Marconi, A. M., Sacchi, V., De Pirro, A., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Villani, P., Cusato, M., Cerioli, A., De Martino, M., Mastroiacovo, P., Moroni, M., Parazzini, F., Vella, S., Floridia, M, Ravizza, M, Masuelli, G, Dalzero, S, Pinnetti, C, Cetin, I, Meloni, A, Spinillo, A, Rubino, E, Francisci, D, Tamburrini, E, Italian Group on Surveillance on Antiretroviral Treatment in, Pregnancy, Martinelli, Pasquale, Floridia M, Ravizza M, Masuelli G, Dalzero S, Pinnetti C, Cetin I, Meloni A, Spinillo A, Rubino E, Francisci D, Tamburrini E, Faldella G, Guerra B, and for the Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,antiretroviral therapy ,MEDLINE ,Human immunodeficiency virus (HIV) ,HIV Infections ,body mass index ,medicine.disease_cause ,Settore MED/17 - MALATTIE INFETTIVE ,Body Mass Index ,BMI ,weight gain ,HIV-1 ,Pregnancy ,Medicine ,Humans ,HIV infection ,pregnancy ,Pregnancy Complications, Infectious ,business.industry ,Obstetrics ,Cesarean Section ,Infectious ,Pregnancy Outcome ,HIV ,medicine.disease ,Pregnancy Complications ,Infectious Diseases ,Italy ,National study ,Female ,medicine.symptom ,business ,Weight gain ,Body mass index - Abstract
Although most of the women (69.4%) had a normal BMI at start of pregnancy, only 37% had an adequate weight gain during pregnancy. Inadequate body weight gain was more common (44.8%) than excessive weight gain (18.2%), but 40% of overweight women and 50% of obese women had an excessive weight gain in pregnancy, with about 9% of the women in these categories gaining >18 kg during pregnancy (Table 1). Only 1.9% of the women had a vaginal delivery; elective and nonelective cesarean deliveries accounted for 81.3% and 16.7% of deliveries, respectively. Compared to underweight/normal women, overweight/obese women had similar occurrences of preterm delivery (23.4% vs 22.7%, P = .871), significantly lower rates of low birthweight (14.2% vs 24.2%, P = .007) and nonelective cesarean deliveries (11.7% vs 18.3%, P = .042), and a significantly higher occurrence of fasting plasma glucose >92 mg/dL at 20–28 weeks (12.1% vs 6.6%, P = .027), hypertension during pregnancy (6.4% vs 2.7%, P = .019), and gestational age–adjusted birthweight >90th percentile (15.5% vs 5.0%, P < .001). Complications of delivery, major birth defects, and HIV transmission were similar between the 2 groups (7.3% vs 7.6%, P = .881; 2.6% vs 3.5%, P = .589; and 0.8% vs 0.5%, P = .661, respectively). An inadequate weight gain during pregnancy was associated with an increased risk of nonelective cesarean delivery (OR, 1.589 [95% CI, 1.077–2.346], P = .020). Excessive weight gain during pregnancy was not associated with either hypertension (OR, 1.364 [95% CI, .537–3.465], P = .514) or 20–28 week glucose level of >92 mg/dL (OR, 0.841 [95% CI, .399–1.772], P = .648), but was significantly associated with birthweight >90th percentile (OR, 2.271 [95% CI, 1.229–4.195], P = .009), and appeared to be protective against low birthweight (OR, 0.544 [95% CI, .323–.918], P = .023) and birthweight
- Published
- 2013
22. Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy
- Author
-
Floridia, M, Ravizza, M, Masuelli, G, Dalzero, S, Pinnetti, C, Cetin, I, Meloni, A, Spinillo, A, Rubino, E, Francisci Dtamburrini, E, Mori, F, Ortolani, P, Dalle Nogare Er, Di Lorenzo, F, Sterrantino, G, Meli, M, Polemi, S, Nocentini, J, Baldini, M, Montorzi, G, Mazzetti, M, Rogasi, P, Borchi, B, Vichi, F, Pinter, E, Anzalone, E, Marocco, R, Mastroianni, C, Mercurio, Vs, Carocci, A, Grilli, E, Maccabruni, A, Zaramella, M, Mariani, B, Natalini Raponi, G, Guaraldi, G, Luzi, K, Nardini, G, Stentarelli, C, Degli Antoni Am, Molinari, A, Crisalli, Mp, Donisi, A, Piepoli, M, Cerri, V, Zuccotti, G, Giacomet, V, Fabiano, V, Placido, G, Vivarelli, A, Castelli, P, Savalli, F, Portelli, V, Sabbatini, F, Francisci, D, Bernini, L, Alberico, S, Maso, G, Tropea, M, Dedoni, M, Cuboni, C, Ortu, F, Piano, P, Citernesi, A, Vicini, I, Roccio, M, Vimercati, A, Miccolis, A, Bassi, E, Guerra, B, Cervi, F, Puccetti, C, Murano, P, Contoli, M, Capretti, Mg, Marsico, C, Faldella, G, Sansone, M, Martinelli, P, Agangi, A, Tibaldi, C, Trentini, L, Todros, T, Garetto, S, Brambilla, T, Savasi, V, Crepaldi, A, Giaquinto, C, Fiscon, M, Rinaldi, R, Bucceri, A, Matrone, R, Scaravelli, G, Fundarò, C, Genovese, O, Cafforio, C, Liuzzi, G, Tozzi, V, Massetti, P, Anceschi, M, Casadei, Am, Cavaliere, Af, Finelli, V, Cellini, M, Castelli Gattinara, G, Marconi, Am, Sacchi, V, De Pirro, A, Polizzi, C, Mattei, A, Pirillo, Mf, Amici, R, Galluzzo, Cm, Donnini, S, Baroncelli, S, Villani, P, Cusato, M, Cerioli, A, De Martino, Maurizio, Mastroiacovo, P, Moroni, M, Parazzini, F, Tamburrini, E, Vella, S, and Martinelli, P.
- Subjects
HIV - Published
- 2013
23. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011
- Author
-
Floridia, M., Mastroiacovo, P., Tamburrini, E., Tibaldi, C., Todros, T., Crepaldi, A., Sansone, M., Fiscon, M., Liuzzi, G., Guerra, B., Vimercati, A., Vichi, F., Vicini, I., Pinnetti, C., Marconi, A. M., Ravizza, M., Mori, F., Ortolani, P., dalle Nogare, E. R., Di Lorenzo, F., Sterrantino, G., Meli, M., Polemi, S., Nocentini, J., Baldini, M., Montorzi, G., Mazzetti, M., Rogasi, P., Borchi, B., Pinter, E., Anzalone, E., Marocco, R., Mastroianni, C., Mercurio, V. S., Carocci, A., Grilli, E., Maccabruni, A., Zaramella, M., Mariani, B., Natalini Raponi, G., Guaraldi, G., Luzi, K., Nardini, G., Stentarelli, C., Degli Antoni, A. M., Molinari, A., Crisalli, M. P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Fabiano, V., Coletto, S., Placido, G., Vivarelli, A., Castelli, P., Savalli, F., Portelli, V., Sabbatini, F., Francisci, D., Bernini, L., Alberico, S., Maso, G., Tropea, M., Meloni, A., Dedoni, M., Cuboni, C., Ortu, F., Piano, P., Citernesi, A., Spinillo, A., Roccio, M., Miccolis, A., Bassi, E., Cervi, F., Puccetti, C., Murano, P., Contoli, M., Capretti, M. G., Marsico, C., Faldella, G., Martinelli, P., Agangi, A., Trentini, L., Masuelli, G., Garetto, S., Cetin, I., Brambilla, T., Savasi, V., Giaquinto, C., Rinaldi, R., Rubino, E., Bucceri, A., Matrone, R., Scaravelli, G., Fundaro, C., Genovese, O., Cafforio, C., Tozzi, V., Massetti, P., Anceschi, M., Casadei, A. M., Cavaliere, A. F., Finelli, V., Cellini, M., Castelli Gattinara, G., Dalzero, S., Sacchi, V., De Pirro, A., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Regazzi, M., Villani, P., Cusato, M., Cerioli, A., De Martino, M., Moroni, M., Parazzini, F., Vella, S., Floridia, M, Mastroiacovo, P, Tamburrini, E, Tibaldi, C, Todros, T, Crepaldi, A, Sansone, M, Fiscon, M, Liuzzi, G, Guerra, B, Vimercati, A, Vichi, F, Vicini, I, Pinnetti, C, Marconi, A, Ravizza, M, Martinelli, Pasquale, and The Italian Group on Surveillance on Antiretroviral Treatment in, Pregnancy
- Subjects
Male ,HIV Infections ,transcriptase inhibitors ,Cohort Studies ,chemistry.chemical_compound ,Pregnancy ,Prevalence ,Birth Weight ,Young adult ,Pregnancy Complications, Infectious ,education.field_of_study ,Obstetrics ,Coinfection ,Antiretroviral therapy ,birth defects ,efavirenz ,HIV ,non-nucleoside reverse transcriptase inhibitors ,nucleoside reverse transcriptase inhibitors ,pregnancy ,protease inhibitors ,women ,Obstetrics and Gynecology ,Abnormalities, Drug-Induced ,Middle Aged ,Italy ,Maternal Exposure ,Reverse Transcriptase Inhibitors ,Female ,Cohort study ,Adult ,medicine.medical_specialty ,Efavirenz ,Adolescent ,Anti-HIV Agents ,Birth weight ,Population ,Antiretroviral Therapy ,Birth defects ,HIV-1 ,Young Adult ,Hepatitis B, Chronic ,medicine ,Humans ,education ,business.industry ,Infant, Newborn ,Odds ratio ,Hepatitis C, Chronic ,medicine.disease ,Infectious Disease Transmission, Vertical ,Surgery ,Pregnancy Trimester, First ,chemistry ,business - Abstract
Objective We used data from a national study of pregnant women with HIV to evaluate the prevalence of congenital abnormalities in newborns from women with HIV infection. Design Observational study. Setting University and hospital clinics. Population Pregnant women with HIV exposed to antiretroviral treatment at any time during pregnancy. Methods The total prevalence of birth defects was assessed on live births, stillbirths, and elective terminations for fetal anomaly. The associations between potentially predictive variables and the occurrence of birth defects were expressed as odds ratios (ORs) with 95% confidence intervals (95% CIs) for exposed versus unexposed cases, calculated in univariate and multivariate logistic regression analyses. Main outcome measures Birth defects, defined according to the Antiretroviral Pregnancy Registry criteria. Results A total of 1257 pregnancies with exposure at any time to antiretroviral therapy were evaluated. Forty-two cases with major defects were observed. The total prevalence was 3.2% (95% CI 1.9–4.5) for exposure to any antiretroviral drug during the first trimester (23 cases with defects) and 3.4% (95% CI 1.9–4.9) for no antiretroviral exposure during the first trimester (19 cases). No associations were found between major birth defects and first-trimester exposure to any antiretroviral treatment (OR 0.94, 95% CI 0.51–1.75), main drug classes (nucleoside reverse transcriptase inhibitors, OR 0.95, 95% CI 0.51–1.76; non-nucleoside reverse transcriptase inhibitors, OR 1.20, 95% CI 0.56–2.55; protease inhibitors, OR 0.92, 95% CI 0.43–1.95), and individual drugs, including efavirenz (prevalence for efavirenz, 2.5%). Conclusions This study adds further support to the assumption that first-trimester exposure to antiretroviral treatment does not increase the risk of congenital abnormalities.
- Published
- 2013
24. Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First‐Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen
- Author
-
Fabbiani, M, primary, Zaccarelli, M, additional, Latini, A, additional, Sterrantino, G, additional, D'Ettorre, G, additional, Grima, P, additional, Mondi, A, additional, Rossetti, B, additional, Borchi, B, additional, Giuliani, M, additional, Antinori, A, additional, De Luca, A, additional, and Di Giambenedetto, S, additional
- Published
- 2015
- Full Text
- View/download PDF
25. Antimicrobial resistance in an intensive care unit before adopting an antibiotic rotation programme for empiric therapy of ventilator-associated pneumonia
- Author
-
Corti, G., Mangani, V., Pecile, P., Borchi, B., Grilli, E., Nicoletti, P., Tulli, G., and Paradisi, F.
- Published
- 2005
26. Darunavir in experienced patients
- Author
-
Sterrantino, G, Borchi, B, Trotta, M, Bartolozzi, D, and Leoncini, F
- Subjects
Darunavir -- Statistics -- Patient outcomes ,HIV patients -- Statistics -- Drug therapy ,Health - Abstract
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, Purpose of the study This study aims to assess the performance of DRV in clinical practice, as part of salvage therapy strategies. Methods We did retrospective assessment of HIV+ patients [...]
- Published
- 2010
- Full Text
- View/download PDF
27. Case Report: Cystic Fibrosis, Lung Transplantation, and the Novel H1N1 Flu
- Author
-
Bresci, S., primary, Borchi, B., additional, Ambu, S., additional, Taccetti, G., additional, Braggion, C., additional, and Leoncini, F., additional
- Published
- 2010
- Full Text
- View/download PDF
28. Case Report: HIV Infection From a Kidney Transplant
- Author
-
Borchi, B., primary, Ambu, S., additional, Bresci, S., additional, Zanazzi, M., additional, Salvadori, M., additional, and Leoncini, F., additional
- Published
- 2010
- Full Text
- View/download PDF
29. Consequences of presentation with advanced HIV disease in pregnancy: Data from a national study in Italy
- Author
-
Floridia, M., Tamburrini, E., Masuelli, G., Guaraldi, G., Molinari, A., Cetin, I., Dalzero, S., Spinillo, A., Liuzzi, G., Pinnetti, C., Vicini, I., Castelli, P., Sacchi, V., Ravizza, M., Mori, F., Ortolani, P., Dalle Nogare, E. R., Di Lorenzo, F., Sterrantino, G., Meli, M., Polemi, S., Nocentini, J., Baldini, M., Montorzi, G., Mazzetti, M., Rogasi, P., Borchi, B., Vichi, F., Del Pin, B., Pinter, E., Anzalone, E., Marocco, R., Claudio Maria MASTROIANNI, Mercurio, V. S., Carocci, A., Grilli, E., Maccabruni, A., Zaramella, M., Mariani, B., Raponi, G. N., Nardini, G., Stentarelli, C., Beghetto, B., Degli Antoni, A. M., Crisalli, M. P., Donisi, A., Piepoli, M., Cerri, V., Zuccotti, G., Giacomet, V., Fabiano, V., Coletto, S., Di Nello, F., Placido, G., Vivarelli, A., Savalli, F., Portelli, V., Sabbatini, F., Francisci, D., Bernini, L., Grossi, P., Rizzi, L., Alberico, S., Maso, G., Airoud, M., Soppelsa, G., Meloni, A., Dedoni, M., Cuboni, C., Ortu, F., Piano, P., Citernesi, A., Vicini, I. B., Luzi, K., Roccio, M., Vimercati, A., Miccolis, A., Gennaro, A., Guerra, B., Cervi, F., Puccetti, C., Margarito, E., Contoli, M., Capretti, M. G., Marsico, C., Faldella, G., Sansone, M., Martinelli, P., Agangi, A., Maruotti, G. M., Tibaldi, C., Trentini, L., Todros, T., Frisina, V., Brambilla, T., Savasi, V., Personeni, C., Giaquinto, C., Fiscon, M., Rinaldi, R., Rubino, E., Bucceri, A., Matrone, R., Scaravelli, G., Fundarò, C., Genovese, O., Cafforio, C., Tozzi, V., Massetti, P., Casadei, A. M., Cavaliere, A. F., Finelli, V., Cellini, M., Gattinara, G. C., Marconi, A. M., Pirro, A., Polizzi, C., Mattei, A., Pirillo, M. F., Amici, R., Galluzzo, C. M., Donnini, S., Baroncelli, S., Cerioli, A., Martino, M., Mastroiacovo, P., Moroni, M., Parazzini, F., and Vella, S.
30. Valacyclovir for cytomegalovirus infection in pregnancy: additional evidences, additional questions
- Author
-
Beatrice Borchi, Lina Rachele Tomasoni, Giuliana Simonazzi, Francesco Castelli, Susanna Giachè, Mariarosaria Di Tommaso, Pierangelo Clerici, Marcello Tavio, Tiziana Lazzarotto, Massimo Andreoni, Irene Campolmi, Lorenzo Zammarchi, Alessandro Bartoloni, Michele Trotta, Luisa Galli, Lucia Pasquini, and Zammarchi L, Lazzarotto T, Andreoni M, Giaché S, Campolmi I, Pasquini L, Di Tommaso M, Simonazzi G, Tomasoni LR, Castelli F, Galli L, Borchi B, Clerici P, Bartoloni A, Tavio M, Trotta M.
- Subjects
Microbiology (medical) ,MEDLINE ,Bioinformatics ,CMV, valacyclovir, gravidanza ,Antiviral Agents ,Pregnancy ,gravidanza ,Humans ,Medicine ,valacyclovir ,Pregnancy Complications, Infectious ,Infectious disease transmission ,business.industry ,Infant, Newborn ,CMV ,virus diseases ,General Medicine ,medicine.disease ,Infectious Disease Transmission, Vertical ,Cytomegalovirus infection ,Infectious Diseases ,Cytomegalovirus Infections ,valacyclovir in pregnant women with primary cytomegalovirus (CMV) infection to prevent vertical transmission ,Female ,business - Abstract
Shortly after the acceptance of our review [1] an additional study on the use of valacyclovir in pregnant women with primary cytomegalovirus (CMV) infection to prevent vertical transmission has been published by De Santis et al [2]. The authors reported a case series of 12 pregnant women treated with off-label valacyclovir 8g per day following primary CMV infection in the first half of pregnancy and stopped in case of negative amniocentesis. The observed rate of positivity at amniocentesis was 17% (2 positive amniocentesis of 12 performed) compatible with a ≈50% reduction of vertical transmission when compared to the 30-35% rate reported in literature [3]. These results are consistent to those reported by Shahar-Nissan K et al in the preliminary report on their clinical placebo-controlled trial [4] and confirm that valacyclovir may reduce the rate of vertical transmission by the time of amniocentesis. However, among the 10 pregnant women with a negative amniocentesis described by De Santis, three delivered a congenitally infected newborn of which one developed moderate unilateral sensory neural loss at 18 months of age. Amongst these three women with negative amniocentesis who delivered a congenitally infected newborn, two presented a new CMV DNAemia after valacyclovir discontinuation. The authors interpret their finding as the result of an efficient control of viral replication and prevention of during the antiviral treatment, with subsequent resurgence of viral and vertical transmission. They suggested the need of controlled trial to evaluate valacyclovir treatment prolonged until the delivery regardless of amniocentesis results. However the possibility of false negative amniocentesis cannot be completely excluded. In particular the authors used 0.4mL of amniotic fluids to extract the CMV-DNA which is lower compared to those used in other reference laboratory (1mL) [5] and this could have affected the sensitivity of the test. In another recent paper (not captured by our review of literature since indexed with the keyword “citomegalovirus” unlike “cytomegalovirus”), De Santis et al described a case series on the use of high dose valacyclovir (8g/day) until delivery in confirmed fetal asymptomatic CMV infections [6]. Of the eleven in utero treated newborns, only one was symptomatic at birth and he developed profound bilateral hearing loss at six month requiring bilateral cochlear implant. Another developed a sensorineural hearing loss at 8 months of age. Surprisingly, three newborns had negative serology and virological tests at birth inducing authors to speculate that treatment can even allow viral clearance in case of low amniotic fluids viral load. To sum up, these two studies confirmed data from previous literature, namely the excellent maternal tolerance and the benefit of valacyclovir in reducing fetal CMV infections at time of amniocentesis [4] and the possible role of the drug in the in utero treatment of confirmed fetal infection [7]. We look forward to see the results of the still partially published randomized, double-blind, placebo-controlled study [4], which will probably add further important information.
- Published
- 2021
31. Prevention, diagnosis and pharmacological treatment of infections in pregnancy: The mobile app GAIA! for healthcare providers and patients.
- Author
-
Bonaiuti R, Zammarchi L, Giaché S, Modi G, Borchi B, Campolmi I, Trotta M, Ravaldi C, Ornaghi S, Di Tommaso M, Bartoloni A, Costa P, Lombardi N, Crescioli G, Vannacci A, and Levi M
- Subjects
- Humans, Pregnancy, Female, Health Personnel, Italy, Mobile Applications, Pregnancy Complications, Infectious drug therapy, Pregnancy Complications, Infectious diagnosis
- Abstract
Objective: To develop and assess the GAIA! app, designed to assist pregnant women and healthcare professionals in managing infectious diseases during pregnancy, and to bridge the information gap between health professionals and expectant mothers., Study Design: This collaborative initiative in Italy involved partnerships with the University of Florence, Careggi University Hospital, and other institutions. The app, built on the Ionic framework, is available on both Apple and Google App Stores. It offers two distinct modes: "healthcare providers" and "patients." Content for the app was derived from extensive literature reviews and clinical guidelines., Results: Since its August 2022 launch, the GAIA! app has garnered over 2,500 downloads, indicating its effectiveness and acceptance within the community. The app differentiates itself from others, such as the Sanford Guide, by focusing specifically on the needs of pregnant women. It ensures cross-platform compatibility, a user-friendly interface, and offline functionality., Conclusions: The GAIA! app has successfully addressed a niche in infectious disease management for pregnant women, gaining significant traction within the community. While it has seen substantial success, challenges like continuous updates and potential language expansion remain. Future endeavors will address these challenges and further evaluate the app's impact on maternal and child health., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipients.
- Author
-
Capone M, Vanni A, Salvati L, Lamacchia G, Mazzoni A, Maggi L, Cosmi L, Liotta F, Romagnani P, Cirillo L, Buti E, Terlizzi V, Azzari C, Citera F, Barbati F, Rossolini GM, Bresci S, Borchi B, Cavallo A, Mencarini J, Francalanci E, Kiros ST, Bartoloni A, and Annunziato F
- Subjects
- Humans, Male, Female, Adult, Vaccination, Middle Aged, Cystic Fibrosis immunology, Immunologic Memory, Organ Transplantation adverse effects, Kidney Transplantation adverse effects, Lung Transplantation adverse effects, Immunization, Secondary, Immunity, Humoral, COVID-19 immunology, COVID-19 prevention & control, SARS-CoV-2 immunology, Transplant Recipients, Immunosuppressive Agents therapeutic use, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, Immunocompromised Host, Immunity, Cellular, Antibodies, Viral immunology, Antibodies, Viral blood
- Abstract
Objective: Novel mRNA-based vaccines have been proven to be powerful tools in combating the global pandemic caused by SARS-CoV-2 protecting individuals, especially the immunocompromised, from COVID-19. Still, it remains largely unknown how solid organ transplant and different immunosuppressive medications affect development of vaccine-induced immunity., Methods: In this work, we monitored humoral and cellular memory responses after mRNA SARS-CoV-2 two-doses and booster doses vaccination in cystic fibrosis lung transplanted patients (CFT) and compared them with both cystic fibrosis patients without lung transplant (CF) and with kidney transplant recipients (KT). In particular, we investigated the effects of immunosuppressive regimens on immune memory to SARS-CoV-2 after mRNA SARS-CoV-2 vaccine in transplanted patients., Results: Our results showed that immunocompromised transplanted patients displayed a weak cellular and humoral memory to SARS-CoV-2 mRNA vaccination. In addition, obtained data clearly demonstrate that immunosuppressive therapy regimen including antimetabolites, further reduces patients' ability to respond to vaccination at both humoral and cell-mediated level. Notably, patient treated with antimetabolites showed a lower humoral and cellular response also after a booster dose vaccination., Conclusion: These results, even if obtained on a small patient's cohort, question whether immunocompromised patients need interventions to improve vaccine SARS-CoV-2 mRNA vaccine response such as additional jab or modulation of immunosuppressive therapy., Competing Interests: Declaration of competing interest Regarding the submission of our manuscript entitled “Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipients”, I'm writing to confirm that the authors declare that they have no conflict of interest., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
33. Asymptomatic CMV infection at birth following maternal primary infection despite valacyclovir treatment and a subsequent negative amniocentesis. Case report.
- Author
-
Toti MS, Zammarchi L, Pasquini L, Campolmi I, Modi G, Borchi B, Bartoloni A, Trotta M, Galli L, and Bernardini R
- Subjects
- Pregnancy, Infant, Newborn, Female, Child, Humans, Valacyclovir therapeutic use, Amniocentesis, Mothers, Infectious Disease Transmission, Vertical prevention & control, Pregnancy Complications, Infectious diagnosis, Pregnancy Complications, Infectious drug therapy, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections drug therapy
- Abstract
Valacyclovir is currently the only pharmacological intervention demonstrated to reduce the risk of vertical CMV congenital infection within a randomized clinical trial in case of primary infection during pregnancy. So far, no data are available on the prognosis of children with congenital CMV infection diagnosed at birth after a negative amniocentesis whose mother were treated with valacyclovir during pregnancy, therefore it is essential to carry out a rigorous neurocognitive follow-up in these children in order to investigate the potential clinical consequence., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
34. Orbital Infiltration in a Patient with Waldenström Macroglobulinemia: Need for Multidisciplinary Approach and Comparison with the Literature.
- Author
-
Paggi R, Mariotti F, Mencarini J, Bresci S, Campolmi I, Bartalesi F, Borchi B, Nassi L, Sordi B, Vannucchi AM, and Bartoloni A
- Abstract
The use of specific inhibitory drugs of intracellular signalling pathways (such as Bruton-Kinase inhibitors) for the treatment of Waldenström's macroglobulinaemia (WM) is a recognised risk factor for Aspergillus spp . infections. The overlapping clinical manifestations of the two diseases may require the involvement of different medical specialities. We describe the clinical course of a patient with pulmonary and encephalic aspergillosis, with concomitant orbital infiltration, which represented a difficult diagnosis: the case required a multidisciplinary approach to define the ocular lesions and an in-depth study of the literature., Competing Interests: Competing interests: The authors declare no conflict of Interest.
- Published
- 2023
- Full Text
- View/download PDF
35. Characteristics of COVID-19 vaccinated and unvaccinated patients admitted to Careggi University Hospital, Florence, Italy.
- Author
-
Paggi R, Barbiero A, Manciulli T, Miftode A, Tilli M, Lagi F, Mencarini J, Borchi B, Pozzi M, Bartalesi F, Spinicci M, Martini L, Coppola A, Nozzoli C, Peris A, Bonizzoli M, Pieralli F, Bartoloni A, and Zammarchi L
- Subjects
- Humans, Middle Aged, Aged, COVID-19 Vaccines, SARS-CoV-2, Hospitals, University, Italy epidemiology, COVID-19 prevention & control
- Abstract
More than 11.5 billion COVID-19 vaccine doses have been administered around the world. Although vaccine effectiveness for severe infections is reported to be 89.0%, breakthrough infections are common and may lead to severe outcome in fragile population. We conducted a real-world observational study on 420 COVID-19 admitted patients from July 2021 to January 2022 in a tertiary level Italian hospital. We collected patient's vaccination and SARS-CoV-2 serological status, SARS-CoV-2 treatments, oxygen supports, intensive (ICU) and subintensive (sub-ICU) care unit admissions, length of staying (LoS) and in-hospital mortality. One-hundred-seventy-two vaccinated and 248 unvaccinated patients were admitted during the study period. Vaccinated group (Vg) had a significantly more elevated Charlson Comorbidity Index than Unvaccinated group (UVg), and no statistical differences were found in terms of in-hospital mortality, LoS or ICU and sub-ICU admissions. Among Vg, anti-S antibodies were detected in 86.18% of patients (seropositives). Vaccinated seronegative patients' in-hospital mortality was significantly higher than vaccinated seropositive patients (33.33% vs 10.69%, p = 0.0055): in particular, mortality rate in 45-69 years old population was higher in vaccinated seronegative group, and comparable in patients ≥ 70 years old. No differences in terms of outcome were registered between Vg and UVg, taking into account that Vg was considerably older and with more comorbidities. In line with other recent observations, higher mortality rate was evidenced for seronegative vaccinated patients. Primary prophylaxis and early treatments result to be necessary, especially for older and immunosuppressed populations., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
36. Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19.
- Author
-
Graziani L, Gori L, Manciulli T, Basile G, Campolmi I, Borchi B, di Dio M, Mattei M, Ciurleo G, Ciliberti M, Malentacchi F, Coppi M, Morettini A, Parronchi P, Rossolini GM, Bartoloni A, Tomassetti S, and Spinicci M
- Subjects
- Humans, COVID-19 Drug Treatment, Immunocompromised Host, Ritonavir therapeutic use, COVID-19
- Published
- 2023
- Full Text
- View/download PDF
37. Infection with SARS-CoV-2 Variants Is Associated with Different Long COVID Phenotypes.
- Author
-
Spinicci M, Graziani L, Tilli M, Nkurunziza J, Vellere I, Borchi B, Mencarini J, Campolmi I, Gori L, Giovannoni L, Amato C, Livi L, Rasero L, Fattirolli F, Marcucci R, Giusti B, Olivotto I, Tomassetti S, Lavorini F, Maggi L, Annunziato F, Marchionni N, Zammarchi L, and Bartoloni A
- Subjects
- Female, Humans, Male, Pandemics, Phenotype, Retrospective Studies, SARS-CoV-2 genetics, Middle Aged, Post-Acute COVID-19 Syndrome, COVID-19 epidemiology, Fatigue Syndrome, Chronic complications
- Abstract
COVID-19 has been associated with a broad range of long-term sequelae, commonly referred to as "long-COVID" or "post-COVID-19" syndrome. Despite an increasing body of literature, long COVID remains poorly characterized. We retrospectively analysed data from electronic medical records of patients admitted to the post-COVID-19 outpatient service of the Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, between June 2020 and June 2021, 4-12 weeks after hospital discharge. A total of 428 patients, 41% women, median age 64 years, underwent a follow-up visit a median 53 days after hospital discharge. Overall, 76% patients reported at least one persistent symptom, including dyspnoea (37%), chronic fatigue (36%), insomnia (16%), visual disorders (13%) and brain fog (13%). Increasing oxygen support (OR 1.4, 95% CI 1.1-1.8), use of immunosuppressants (OR 6.4, 95% CI 1.5-28) and female sex (OR 1.8, 95% CI 1.1-2.9) were associated with a higher risk of long COVID symptoms. Comparison between symptomatic patients infected in the period March-December 2020 (prevalent circulation of wild-type SARS-CoV-2) with those infected in the period January-April 2021 (prevalent circulation of B.1.1.7 Alpha variant) showed a significant modification in the pattern of symptoms belonging to the neurological and cognitive/emotional categories. Our findings confirmed shortness of breath and chronic fatigue as the most frequent long COVID manifestations, while female sex and severe COVID-19 course were the main risk factors for developing lingering symptoms. SARS-CoV-2 variants may induce different long COVID phenotypes, possibly due to changes in cell tropism and differences in viral-host interaction.
- Published
- 2022
- Full Text
- View/download PDF
38. Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy.
- Author
-
Manciulli T, Modi G, Campolmi I, Borchi B, Trotta M, Spinicci M, Lagi F, Bartoloni A, and Zammarchi L
- Subjects
- Adult, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antibodies, Viral, Antiviral Agents, Female, Humans, Infant, Oxygen, Postpartum Period, Pregnancy, COVID-19 Drug Treatment
- Abstract
Purpose: Pregnant and postpartum women are at increased risk of developing severe COVID-19. Monoclonal antibodies (mAbs) are now widely used in high-income countries to treat mild to moderate COVID-19 outpatients at risk for developing severe disease. Very few data are available on the use of mAbs in special populations, including pregnant and postpartum women. Here we present our early experience with mAbs in these two populations., Methods: Electronic records of pregnant and postpartum women treated with mAbs at Careggi University Hospital, Florence, were retrieved. Relevant data were extracted (age, presence of risk factors for COVID-19, oxygen support, mAb type, gestational age, and pregnancy status). When available, outcomes at 28 days after administration were also included., Results: From March 1st to September 30th 2021, eight pregnant and two postpartum women have been treated with mAbs at our center. The median age was 31 years (IQR 30-33.5, range 29-38), median gestational age was 24 weeks. Seven patients had additional risk factors. According to the Italian disposition, all patients received casirivimab/imdevimab, with five receiving a 2.4 mg dose and five receiving a 8 g dose. Eight patients improved. One developed myocarditis, considered a COVID-19 complication. Another required a transient increase of low flow oxygen support before improving and being discharged. At a 28 days follow-up, all patients were clinically recovered. We did not observe mAbs related adverse events., Conclusion: Although preliminary data should be interpreted with caution, it is remarkable how mAbs were well tolerated by pregnant women with COVID-19. Further data on mAbs in this special population should be collected but the use of mAbs in pregnant and postpartum patients should be considered. Even thus oral antivirals are becoming available, they are not recommended in pregnant and postpartum women. This population may specifically benefit from treatment with last generation mAbs., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
39. AIDS patient with severe T cell depletion achieved control but not clearance of SARS-CoV-2 infection.
- Author
-
Spinicci M, Mazzoni A, Borchi B, Graziani L, Mazzetti M, Bartalesi F, Botta A, Tilli M, Pieralli F, Coppi M, Giovacchini N, Colao MG, Saccardi R, Rossolini GM, Annunziato F, and Bartoloni A
- Subjects
- Acquired Immunodeficiency Syndrome blood, Adult, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes metabolism, COVID-19 blood, Female, Humans, SARS-CoV-2 metabolism, Acquired Immunodeficiency Syndrome immunology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, COVID-19 immunology, SARS-CoV-2 immunology
- Abstract
A late presenter AIDS patient with severe T cell depletion presented non-severe COVID-19 symptoms, with prolonged viral shedding. Our case report supports the hypothesis that an effective T cell response may be dispensable for the control of COVID-19 progression to severe forms, while it may be necessary for SARS-CoV-2 clearance., (© 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.)
- Published
- 2022
- Full Text
- View/download PDF
40. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
- Author
-
Lagi F, Botta A, Kiros ST, Meli M, Borchi B, Cavallo A, Pozzi M, Bartoloni A, and Sterrantino G
- Subjects
- Adult, Cohort Studies, Female, HIV-1, Humans, Immunocompromised Host, Italy, Male, Middle Aged, Treatment Outcome, Anti-HIV Agents therapeutic use, Drug Combinations, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination therapeutic use, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use, Lamivudine therapeutic use, Rilpivirine therapeutic use
- Abstract
This study evaluated the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC (RPV-STR) or DTG/ABC/3TC (DTG-STR) in virologically-suppressed HIV-positive patients in a single Italian centre. All HIV-infected ART-experienced patients switching to RPV-STR or DTG-STR with HIV-RNA <50 copies/mL were included. Outcomes were incidence rate and rate ratios for discontinuation due to all causes (DAC), to adverse events (DAE) and to virological failure (VF) after 4 years of follow-up. We included 402 patients (244 on RPV-STR, 158 on DTG-STR). At Year 4 of follow-up, 124 patients (30.8%) discontinued for any cause (71 on RPV-STR, 53 on DTG-STR). Fifteen patients experienced VF [13 (5.3%) on RPV-STR and 2 (1.3%) on DTG-STR; log-rank, P = 0.4413]. Overall, 46 patients (11.4%) had AEs (23 on RPV-STR, 23 on DTG-STR). Nausea/diarrhoea was more frequent with DTG-STR (4.4% vs. 0%) and neurological toxicity with RPV-STR (4.5% vs. 2.5%). The rate of DAC within the first 3 months was significantly higher with DTG-STR (aRR = 5.88, 95% CI 3.20-10.81; P < 0.001); similarly, the discontinuation rate due to AEs was significantly higher with DTG-STR compared with RPV-STR (aRR = 12.89, 95% CI 5.48-30.32; P < 0.001). No difference in VF was observed between the two groups (RR = 0.47, 95% CI 0.10-2.14; P = 0.335). Patients with undetectable viral load who switched to DTG-STR or RPV-STR maintained virological suppression with a low risk of VF. A higher discontinuation rate was observed with DTG-STR compared with RPV-STR, particularly within 3 months from switch., Competing Interests: Declaration of Competing Interests None declared., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
41. Primary toxoplasmosis acquired during early pregnancy: Is it currently overestimated?
- Author
-
Trotta M, Trotta A, Spataro E, Giache S, Borchi B, Zammarchi L, Campolmi I, Galli L, and Pasquini L
- Subjects
- Amniotic Fluid, Antibodies, Protozoan, Antibody Affinity, Female, Humans, Immunoglobulin G, Infant, Newborn, Pregnancy, Retrospective Studies, Pregnancy Complications, Infectious diagnosis, Pregnancy Complications, Infectious epidemiology, Toxoplasmosis diagnosis, Toxoplasmosis epidemiology
- Abstract
Objective: Toxoplasmosis acquired in early pregnancy is a potentially severe complication for the fetus. Evaluating the risk of transplacental infection in pregnant women accessing the Tuscany Reference Center for Infectious Diseases in Pregnancy during the last 20 years with suspected or confirmed toxoplasmosis acquired in early pregnancy was the aim of the study., Study Design: We retrospectively enrolled all pregnant women undergoing amniocentesis for toxoplasmosis acquired in the first 16 gestational weeks in the period 1999-2019, comparing patients with certain acute infection (seroconversion occurred in pregnancy, CAIP) with those with suspected acute infection (IgG positive with low/intermediate IgG avidity index, SAIP)., Results: 237 patients were enrolled, 187 (78.9%) with SAIP and 50 (21.1%) with CAIP. Specific IgM was detected in 47.5% and 76.7% (p-value 0.001), and the mean IgG avidity index was 22.7% and 7.1% (p-value < 0.001) in the SAIP and in the CAIP group, respectively. The mean delay from diagnosis to antibiotic initiation was 14.6 in SAIP and 11 days in CAIP group. Toxoplasma DNA was detected in the amniotic fluid in one case in a patient with CAIP. Excluding 24 newborns with not available data, prevalence of congenital infection was 0.47% [1/213 (95% CI 0.08%-2.61%)], 0% [0/178 (95% CI 0%-2.11%)] in SAIP and 2.8% [1/35 (95% CI 0.51%-14.53%)] in CAIP group., Conclusions: Toxoplasmosis acquired in early pregnancy has a low risk of fetal infection. Actively discussing case-by-case amniocentesis indication with patients, especially when a recent toxoplasmosis is not properly confirmed, is desirable., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
42. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.
- Author
-
Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni A, De Socio GV, Luchi S, Blanc P, Puoti M, Toschi E, Massari M, Palmisano L, Marano G, Chiamenti M, Martinelli L, Franchi S, Pallotto C, Suardi LR, Luciani Pasqua B, Merli M, Fabiani P, Bertolucci L, Borchi B, Modica S, Moneta S, Marchetti G, d'Arminio Monforte A, Stoppini L, Ferracchiato N, Piconi S, Fabbri C, Beccastrini E, Saccardi R, Giacometti A, Esperti S, Pierotti P, Bernini L, Bianco C, Benedetti S, Lanzi A, Bonfanti P, Massari M, Sani S, Saracino A, Castagna A, Trabace L, Lanza M, Focosi D, Mazzoni A, Pistello M, and Falcone M
- Subjects
- Aged, COVID-19 complications, COVID-19 mortality, Disease Progression, Female, Humans, Italy, Male, Middle Aged, Prospective Studies, SARS-CoV-2, Severity of Illness Index, Standard of Care, COVID-19 Serotherapy, COVID-19 therapy, Hospital Mortality, Hospitalization, Immunization, Passive, Plasma, Respiratory Insufficiency
- Abstract
Importance: Convalescent plasma (CP) has been generally unsuccessful in preventing worsening of respiratory failure or death in hospitalized patients with COVID-19 pneumonia., Objective: To evaluate the efficacy of CP plus standard therapy (ST) vs ST alone in preventing worsening respiratory failure or death in patients with COVID-19 pneumonia., Design, Setting, and Participants: This prospective, open-label, randomized clinical trial enrolled (1:1 ratio) hospitalized patients with COVID-19 pneumonia to receive CP plus ST or ST alone between July 15 and December 8, 2020, at 27 clinical sites in Italy. Hospitalized adults with COVID-19 pneumonia and a partial pressure of oxygen-to-fraction of inspired oxygen (Pao2/Fio2) ratio between 350 and 200 mm Hg were eligible., Interventions: Patients in the experimental group received intravenous high-titer CP (≥1:160, by microneutralization test) plus ST. The volume of infused CP was 200 mL given from 1 to a maximum of 3 infusions. Patients in the control group received ST, represented by remdesivir, glucocorticoids, and low-molecular weight heparin, according to the Agenzia Italiana del Farmaco recommendations., Main Outcomes and Measures: The primary outcome was a composite of worsening respiratory failure (Pao2/Fio2 ratio <150 mm Hg) or death within 30 days from randomization., Results: Of the 487 randomized patients (241 to CP plus ST; 246 to ST alone), 312 (64.1%) were men; the median (IQR) age was 64 (54.0-74.0) years. The modified intention-to-treat population included 473 patients. The primary end point occurred in 59 of 231 patients (25.5%) treated with CP and ST and in 67 of 239 patients (28.0%) who received ST (odds ratio, 0.88; 95% CI, 0.59-1.33; P = .54). Adverse events occurred more frequently in the CP group (12 of 241 [5.0%]) compared with the control group (4 of 246 [1.6%]; P = .04)., Conclusions and Relevance: In patients with moderate to severe COVID-19 pneumonia, high-titer anti-SARS-CoV-2 CP did not reduce the progression to severe respiratory failure or death within 30 days., Trial Registration: ClinicalTrials.gov Identifier: NCT04716556.
- Published
- 2021
- Full Text
- View/download PDF
43. Ceftolozane/tazobactam for Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis adult patients: a case series.
- Author
-
Ottino L, Bartalesi F, Borchi B, Bresci S, Cavallo A, Baccani I, Rossolini GM, and Bartoloni A
- Subjects
- Adolescent, Adult, Cystic Fibrosis microbiology, Humans, Italy, Male, Microbial Sensitivity Tests, Middle Aged, Pseudomonas Infections microbiology, Pseudomonas aeruginosa genetics, Pseudomonas aeruginosa isolation & purification, Pseudomonas aeruginosa physiology, Sputum microbiology, Young Adult, Anti-Bacterial Agents therapeutic use, Cephalosporins therapeutic use, Cystic Fibrosis drug therapy, Lung microbiology, Pseudomonas Infections drug therapy, Pseudomonas aeruginosa drug effects, Tazobactam therapeutic use
- Abstract
Management of cystic fibrosis (CF) patients colonized with Pseudomonas aeruginosa is challenging due to its virulence and multi-drug resistance. Ceftolozane/tazobactam (C/T) is a promising new antipseudomonal agent, and clinical data on CF are limited. We describe our experience in the use of C/T for P. aeruginosa-related pulmonary exacerbations (PE) in CF adults admitted within 2016 and 2019 at Careggi Hospital, Florence, Italy. PE was diagnosed as deterioration of respiratory function, worsening cough, and increasing of sputum. C/T was given at the dose of 3 g every 8 h. C/T was used in ten patients. Mean length of C/T treatment was 16.3 days, and tobramycin was the most frequently combined antipseudomonal agent. All patients were successfully treated although susceptibility testing on sputum sample showed C/T resistance in two cases. No adverse effects related to C/T were reported. To our knowledge this is the largest case series on CF patients treated with C/T. Clinical responses were encouraging even where C/T resistant P. aeruginosa was isolated, probably due to multiple phenotypes colonizing CF lungs. C/T could play a promising role in combination therapy against P. aeruginosa as a part of a colistin-sparing regime., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
44. Strongyloidiasis in the COVID era: a warning for an implementation of the screening protocol.
- Author
-
Vellere I, Graziani L, Tilli M, Mantella A, Campolmi I, Mencarini J, Borchi B, Spinicci M, Antonelli A, Rossolini GM, Bartoloni A, and Zammarchi L
- Subjects
- Animals, Humans, Mass Screening, COVID-19 diagnosis, Strongyloides stercoralis, Strongyloidiasis diagnosis
- Published
- 2021
- Full Text
- View/download PDF
45. Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy.
- Author
-
Lagi F, Trevisan S, Piccica M, Graziani L, Basile G, Mencarini J, Borchi B, Menicacci L, Vaudo M, Scotti V, Fabbri A, Bandini G, Tozzetti C, Berni A, Aiezza N, Pestelli G, Turchi V, Pignone AM, Poggesi L, Nozzoli C, Morettini A, Rossolini GM, and Bartoloni A
- Subjects
- COVID-19 Testing, Humans, Italy epidemiology, Point-of-Care Testing, Prospective Studies, Sensitivity and Specificity, COVID-19, SARS-CoV-2
- Abstract
Objective: Evaluate the real-world accuracy of Myxovirus resistance protein A (MxA) detected by the rapid, point-of-care FebriDx test during the second-wave pandemic in Italy in patients with acute respiratory infection (ARI) and a clinical suspicion of COVID-19., Design and Methods: Prospective, observational, diagnostic accuracy study whereby hospitalized patients with ARI were consecutively enrolled in a single tertiary care center in Italy from August 1, 2020 to January 31, 2021., Results: COVID-19 was diagnosed in 136/200 (68.0%) patients and Non-COVID-19 was diagnosed in 64/200 (32.0%) patients. COVID-19 patients were younger and had a lower Charlson comorbidity index compared to Non-COVID-19 patients (p < 0.001). Concordance between FebriDx, MxA and rt-PCR for SARS-CoV-2 (gold standard) was good (k 0.93, 95% CI 0.87-0.99). Overall sensitivity and specificity were 97.8% [95% CI 93.7-99.5] and 95.3% [95% CI 86.9%-99.0%], respectively. FebriDx demonstrated a negative predictive value of 95.3% (95% CI 86.9-99.0) for an observed disease prevalence of 68%., Conclusions: FebriDx MxA showed high diagnostic accuracy to identify COVID-19 and could be considered as a real-time triage tool to streamline the management of suspected COVID-19 patients. FebriDx also detected bacterial etiology in Non-COVID-19 patients suggesting good performance to distinguish bacterial from viral respiratory infection., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
46. Valacyclovir for prevention and treatment of fetal CMV infection: inclusion in the Law 648/96 list and launch of the Italian multicentre observational prospective study "MEGAL-ITALI".
- Author
-
Zammarchi L, Lazzarotto T, Di Tommaso M, Tomasoni L, Pasquini L, Galli L, Simonazzi G, Castelli F, Borchi B, Campolmi I, Ornaghi S, Bartoloni A, Andreoni M, Pagano I, Petraglia S, Ramenghi L, Clerici P, Tavio M, and Trotta M
- Subjects
- Antiviral Agents therapeutic use, Humans, Infant, Newborn, Italy, Cytomegalovirus Infections congenital, Cytomegalovirus Infections drug therapy, Cytomegalovirus Infections prevention & control, Valacyclovir therapeutic use
- Abstract
Not available.
- Published
- 2021
47. Hand, foot, and mouth disease in pregnancy: 7 years Tuscan experience and literature review.
- Author
-
Giachè S, Borchi B, Zammarchi L, Colao MG, Ciccone N, Sterrantino G, Rossolini GM, Bartoloni A, and Trotta M
- Subjects
- China, Female, Humans, Infant, Infant, Newborn, Pregnancy, Enterovirus, Hand, Foot and Mouth Disease diagnosis, Hand, Foot and Mouth Disease epidemiology
- Abstract
Objective: Evaluation of hand, foot, and mouth disease (HFMD) diagnostic strategies in pregnancy and the risk of HFMD-related fetopathy., Study Design: Pregnant women consecutively evaluated between 2010 and 2016 at the Tuscany Reference Center for Infectious Diseases in Pregnancy for HFMD were enrolled. A descriptive analysis of infected patients/newborns data and literature review were carried out., Result: Of the 128 women evaluated, 52 (41%) were symptomatic: 32 (61.5%) developed HFM vesicles, 12 (23%) palmoplantar vesicles, and 8 (15.5%) oral aphthae. Serological positivity and direct Enterovirus detection on blood and vesicle were obtained in 1.9% (1/52), 9.1% (1/11), and 68.7% (11/16), respectively. Three miscarriage and few cases of fetal/neonatal anomalies were reported., Conclusion: HFMD diagnosis is primarily a clinical diagnosis. Direct viral detection is more sensitive than serology. Considering our series and literature review, data on embryo-fetal-neonatal outcomes are not conclusive. Although the role of EV as causative agents of congenital defects remains uncertain, the described cases of unfavorable outcome impose prudence and monitoring of pregnant women with HFMD throughout the gestation.
- Published
- 2021
- Full Text
- View/download PDF
48. Valacyclovir for cytomegalovirus infection in pregnancy: additional evidences, additional questions.
- Author
-
Zammarchi L, Lazzarotto T, Andreoni M, Giaché S, Campolmi I, Pasquini L, Di Tommaso M, Simonazzi G, Tomasoni LR, Castelli F, Galli L, Borchi B, Clerici P, Bartoloni A, Tavio M, and Trotta M
- Subjects
- Antiviral Agents adverse effects, Female, Humans, Infant, Newborn, Infectious Disease Transmission, Vertical prevention & control, Pregnancy, Valacyclovir adverse effects, Antiviral Agents therapeutic use, Cytomegalovirus Infections drug therapy, Pregnancy Complications, Infectious drug therapy, Valacyclovir therapeutic use
- Published
- 2021
- Full Text
- View/download PDF
49. Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center.
- Author
-
Spinicci M, Vellere I, Graziani L, Tilli M, Borchi B, Mencarini J, Campolmi I, Gori L, Rasero L, Fattirolli F, Olivotto I, Lavorini F, Marchionni N, Zammarchi L, and Bartoloni A
- Abstract
We evaluated 100 postacute coronavirus disease 2019 (COVID-19) patients a median (interquartile range) of 60 (48-67) days after discharge from the Careggi University Hospital, Italy. Eighty-four (84%) had at least 1 persistent symptom, irrespective of COVID-19 severity. A considerable number of hospital readmissions (10%) and/or infectious diseases (14%) during the postdischarge period were reported., (© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2021
- Full Text
- View/download PDF
50. Should obstetricians working in non-endemic countries care about emerging tropical diseases?
- Author
-
Giaché S, Modi G, Borchi B, Campolmi I, Trotta M, Di Tommaso M, Seravalli V, Bartoloni A, and Zammarchi L
- Subjects
- Female, Humans, Infant, Newborn, Pregnancy, Prevalence, Travel, Zika Virus, Zika Virus Infection diagnosis, Zika Virus Infection epidemiology, Zika Virus Infection therapy
- Abstract
Due to migration and international travels, obstetricians are increasingly faced with a globalized obstetric setting and should adapt their daily clinical and diagnostic approach to the modifications of tropical and subtropical infections epidemiology. This paper is focused on five emerging infectious diseases, namely Chagas disease, HTLV-1 infection, malaria, schistosomiasis and Zika virus infection, having a high prevalence in migrant populations and which can affect international travelers. These diseases frequently pass unrecognized since they are characterized by few or no symptoms during pregnancy, however they may cause a relevant maternal, fetal and neonatal impact. Specific and reliable diagnostic and treatment options are available but are rarely used during routine obstetrical practice., Competing Interests: Declaration of Competing Interest The authors report no declarations of interest., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.